An interventional study of Environmental Visual Distraction (Virtual Window) and The control group receives nitrous oxide (N₂O) analgesia, which is a drug intervention, even though it is part of routine clinical practice. in Pain During Outpatient Hysteroscopy, sponsored by Ospedale degli Infermi di Biella. Recruiting at 1 site in Italy. Open to female participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Ospedale degli Infermi di Biella · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Pain with a site in Italy — 35 open to participants now, 41 under way, 1 of them phase 3. Pain · Italy.
Among the 213 studies in Pain with a site in Italy, this one is the 109th largest by planned enrollment of the 156 interventional ones that give a count, is one of 8 that started in 2026, is one of 102 with no phase, reaches primary completion later than 22 of the 40 other live ones, and was the 200th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →35 of the 213 studies in Pain with a site in Italy are open now. Recruiting first, the newest first:
Fisiopoint Parma Physiotherapy · Sites in Italy
Ages 18–75
Universita di Verona · Sites in Italy
Ages 18+
Catholic University of the Sacred Heart · Sites in Italy
Ages 18–79 · Healthy volunteers
Istituto Oncologico Veneto IRCCS · Sites in Italy
Ages 18–99
Università degli Studi del Piemonte Orientale Amedeo Avogadro · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 25 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 30 · Phase 4 13
First in 2003; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 80 across the 156 interventional studies, 142 across the 56 observational. Of the 139 that completed or were terminated, 19 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 213 have an industry lead sponsor. The 10 most frequent:
Ospedale degli Infermi di Biella is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Ospedale degli Infermi di Biella has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
11 of the studies in Pain with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07646795Martina StefaniniAlveolar Ridge Reconstruction in Post-extraction Sites Using a Magnesium Resorbable Membrane. An Explorative Study | 2026-11-27 |
| NCT05666921Meyer Children's Hospital IRCCSAlexithymia and Attachment Style in Patients With Somatic Symptoms | 2026-12 |
| NCT07338292Istituto Oncologico Veneto IRCCSVIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures | 2026-12-31 |
| NCT07123805Fondazione IRCCS Policlinico San Matteo di PaviaACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery | 2026-12-31 |
| NCT06409832University of FlorenceRimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 213 studies in Pain with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This document describes the protocol of a pilot randomized clinical study evaluating the effect of environmental visual distraction combined with nitrous oxide (N₂O) analgesia on the procedural experience of patients undergoing outpatient operative hysteroscopy at the Hysteroscopy Unit of ASL Biella.
Office hysteroscopy is widely used for the diagnosis and treatment of intrauterine conditions such as abnormal uterine bleeding, infertility, and endocavitary pathology. Thanks to technological advances and the miniaturization of instruments, many procedures can now be performed in an outpatient setting without general anesthesia. However, pain perception and procedural anxiety may limit patient tolerance and the completion of the examination.
Nitrous oxide is commonly used for analgesia in outpatient hysteroscopy due to its rapid onset, reversibility, and favorable safety profile. It allows effective pain control without deep sedation and enables quick patient recovery after the procedure.
In addition to pharmacological approaches, environmental strategies aimed at reducing anxiety and discomfort are increasingly studied. In this protocol, a virtual environmental window-a wall-mounted screen displaying relaxing videos such as natural landscapes or marine scenes-is used as a visual distraction tool to potentially improve the patient's procedural experience.
The primary objective is to evaluate the effect of the environmental setting on the patient's experience during hysteroscopy, measured using the Visual Analogue Scale (VAS) for pain after the procedure. The secondary outcome is the rate of referral to the operating room following outpatient hysteroscopy. Results will also be stratified by parity and hysteroscopic instrument used.
The study will enroll 50 patients aged 25-60 years who are eligible for outpatient hysteroscopy and nitrous oxide analgesia. Participants will be randomized into two groups using sealed envelopes. The intervention group will receive nitrous oxide combined with visual environmental distraction, while the control group will receive nitrous oxide alone according to routine clinical practice.
After the procedure, patients will complete the VAS pain scale (0-10) to assess the pain experienced during the intervention. Clinical and procedural data will be collected and analyzed using descriptive and exploratory statistical methods. Outcome assessors will be blinded to group allocation.
The study follows international ethical standards, including the Declaration of Helsinki, Good Clinical Practice guidelines, and European data protection regulations (GDPR). Nitrous oxide is part of routine care and is not the experimental component of the study.
Overall, this pilot study aims to explore whether a simple non-pharmacological environmental intervention can reduce perceived pain and improve patient tolerance during outpatient hysteroscopy, providing preliminary data for future larger studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Candidates for outpatient hysteroscopy
Clinically eligible for nitrous oxide (N₂O) analgesia according to routine clinical practice
Able to understand and sign
Exclusion Criteria:
Known or suspected pneumothorax
Severe obstructive pulmonary disease
Confusional state or altered consciousness
Confirmed or suspected pregnancy
Previous major cervical surgery (e.g., conization)
Refusal or withdrawal of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A wall-mounted screen displaying relaxing visual content (e.g., natural landscapes, ocean scenes, or aquarium environments) is activated during outpatient hysteroscopy to provide environmental visual distraction. The visual stimulus begins approximately 5 minutes before the procedure and continues throughout the intervention. This non-pharmacological environmental support is used in addition to standard analgesia with nitrous oxide (N₂O) to potentially reduce perceived pain and improve patient comfort during the procedure.
Procedure: Environmental Visual Distraction (Virtual Window)
Patients receive nitrous oxide (N₂O) analgesia alone according to routine clinical practice during outpatient hysteroscopy.
Drug: The control group receives nitrous oxide (N₂O) analgesia, which is a drug intervention, even though it is part of routine clinical practice.
A wall-mounted screen displaying relaxing visual content (e.g., natural landscapes, ocean scenes, or aquarium environments) is activated during outpatient hysteroscopy to provide environmental visual distraction. The visual stimulus begins approximately 5 minutes before the procedure and continues throughout the intervention. This non-pharmacological environmental support is used in addition to standard analgesia with nitrous oxide (N₂O) to potentially reduce perceived pain and improve patient comfort during the procedure.
Patients receive inhaled nitrous oxide (N₂O) administered through a buccal-nasal mask starting approximately 5 minutes before the outpatient hysteroscopy procedure and continuing throughout the intervention. Nitrous oxide is used as routine analgesia according to standard clinical practice to reduce pain and anxiety during the procedure. No environmental visual distraction or additional experimental intervention is applied in this group.
Pain intensity during outpatient hysteroscopy measured by Visual Analogue Scale (VAS)
Pain perceived during the hysteroscopy procedure measured using the Visual Analogue Scale (VAS) from 0 (no pain) to 10 (worst imaginable pain), assessed immediately after the procedure.
Time frame: Immediately after completion of the hysteroscopy procedure (within 5 minutes).
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 5 months is below that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ospedale degli Infermi di Biella